Lead Product(s) : Daxdilimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Daxdilimab (HZN-7734) is an anti-ILT7 human monoclonal antibody that depletes certain dendritic cells. Depleting these cells may interrupt the cycle of inflammation that causes tissue damage in a variety of autoimmune conditions.
Product Name : HZN-7734
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Daxdilimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable